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regression methods to address ceiling and floor effects evident both theoretically
and empirically. Also, future descriptive systems and tariff valuation processes
should incorporate values that exceed ‘full health’ (1.0) as is currently done for
‘death’ (0.0).
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OBJECTIVES: The objectives of this study were to investigate whether medication
adherence and persistence differed across: (1) responders vs. non-responders; and
(2) early vs. late responders to a survey assessing medication and health beliefs.
METHODS: A survey assessing medication and health beliefs was mailed to pa-
tientswho filled a qualifying index prescription for one of five chronic conditions at
one national and two regional retail pharmacies in 2008. Adherence and persis-
tence to the index drug class was measured using pharmacy claims data over 12
months. A multivariate generalized linear model with a negative binomial distri-
bution and log-link function was used to determine the significant predictors of
adherence. Kaplan-Meier estimates of survival (persistence) curves were used to
assess the time to discontinuation, and the multivariate Cox proportional hazards
model was used to identify significant predictors of non-persistence. To assess
differences between early vs. late responders, medication beliefs were compared
across timing quartiles based on survey response time (date signed minus date
mailed). RESULTS: A final survey response rate of 24.25% was achieved. Survey
non-responders had statistically significantly lower medication adherence than
responders. As assessed by the log-rank test, the Kaplan-Meier estimate of the
persistence curve for responders was statistically significantly higher (indicating
better persistence) than the one for non-responders These results were confirmed
by the multivariate Cox proportional hazards model for time-to-discontinuation
outcome. Compared to early survey responders, late responders reported less per-
ceived need (p.003), more medication concerns (p.031), less prescription-medi-
cation knowledge (p.008), and less trust in their prescribing physician (p.002).
CONCLUSIONS:Our study found evidence of non-response bias in a survey assess-
ing patients’medication andhealth beliefs. Non-response bias by adherence status
can result in biased estimates ofmedication beliefs.We recommendusingmultiple
survey levers to increase response rate among non-adherent patients to reduce the
potential for non-response bias.
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OBJECTIVES: To identify trends in the use of direct and indirect utility elicitation
techniques in published cost-effectiveness analyses.METHODS:We analyzed data
extracted from cost-effectiveness analyses (CEAs) included in the Tufts Medical
Center Cost-effectiveness Analysis Registry, a database with detailed information
on CEAs published in the peer-reviewed medical and economic literatures. Using
studies from 1991-2008, we analyzed the proportion of utilityweights elicited using
direct vs. indirect methods, type of direct or indirect elicitation method, source of
weights, age of the population affected by the disease, and disease category.
RESULTS: For CEAs published from1991 to 2008, 42%of utilityweightswere elicited
using direct elicitation methods, 35% using indirect methods, and methods were
not reported for 23%. During this time, the proportion of direct and indirect re-
mained similar. For direct methods in adults, the rating scale remainedmost com-
mon (25% for ‘91-‘93 and ‘06-‘08). For direct methods in child health, author/clini-
cian judgment was most common in earlier years (91%) compared with the
standard gamble later (31%). For indirect methods, the most common method in
recent years was the EQ-5D for adults and the HUI for children. Trends in the
identified source of utility weights demonstrated an increase in patient or commu-
nity members as the source accompanied by a decline in clinicians or authors as
the source. Specific characteristics of utility weights were missing for 6-60% of
utility weights depending on the year. CONCLUSIONS: Trends over time show
increasing adherence to guideline recommendations. A substantial proportion of
CEAs using direct elicitation methods in recent years suggests there may be a
continued role for direct elicitation for certain populations or types of health. The
high proportion of studies lacking details for health utilities suggests greater at-
tention needs to be paid toward providing transparency in utility weights for pub-
lished cost-effectiveness analyses.
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OBJECTIVES: Electronic Patient Reported Outcomes (ePRO) is a growing to be a
preferred selection for collection of Patient Reported Outcomes (PRO) data. How-
ever, there are a number of PRO instruments that are only available in paper ver-
sion. Researchers may be unaware of steps required for converting paper to elec-
tronic versions and that different steps may be required pending on level of
modification involved. This presentation intends to provide guidance for identify-
ing required steps in converting paper to ePRO and to identify FDA’s PRO Guidance
as a resource.METHODS: Required actions can be determined with input from the
following: original author, psychometrician, FDA reviewer, etc. It is the Research-
er’s responsibility to determine the action plan on received input. Actions to dem-
onstrate measurement equivalence include: clinical reviews, cognitive debriefs,
usability testing, equivalence testing and full psychometric testing. Since the de-
cision is determined based on the magnitude of modification, it is important to
distinguish each level of modification. This session will provide examples with
application of FDA’s PRO guidance. RESULTS: Examples: Small – modifications
such as changing wording from ”circle yes/no” to ”press 1 for yes, press 2 for no”;
clinical review, small scale cognitive and usability testing would likely be recom-
mended. Medium – modifications such as changing sentence structure or format;
clinical review, cognitive debrief, and some usability testing would likely be re-
quired. Large – modifications such as removing items or scale anchors, changing
question wording; a full validation study and large scale usability testing would
likely be necessary. CONCLUSIONS: Classification of level of modification is based
on the potential effect on the original version’s meaning. Demonstration that the
modified version has either equivalent or superior psychometric properties in re-
spect to the original version is important, as failure to do so may result in serious
consequences for trials where the modified version is used.
PRM22
STAGES OF NON-PERSISTENCE: A NOVEL WAY OF FRAMING LONGITUDINAL
PERSISTENCE TO CHRONIC MEDICATIONS
Gadkari A, McHorney C
Merck & Co., Inc, North Wales, PA, USA
OBJECTIVES: The objective of this study is to propose and provide preliminary
evidence of validity of a novel, staging approach for framing longitudinal persis-
tence to chronic medications. METHODS: A survey assessing medication and
health beliefs was mailed to patients with one of five chronic conditions in 2008.
Multi-item scales assessed perceived need for medications (k8), side-effect con-
cerns (k5), perceived medication affordability (k4), perceived disease severity
(k4), trust in physician (k2), medication-safety concerns (k3), and perceived
value of prescription medications (k1). Persistence over 14 months was assessed
using the continuous measure of medication gaps (CMG) from pharmacy claims
data. Patients were categorized in one of the following six mutually-exclusive cat-
egories: (1) non-persistent after first fill; (2) non-persistent after second fill; (3)
non-persistent after third fill; (4) non-persistent after fourth or subsequent fill; (5)
persistent across 14 months but with gaps in therapy; and (6) persistent across 14
months with no gaps in therapy. Mean scores for the belief scales were compared
across the six stages, and multivariate regression models were used to assess
whether scores differed significantly across stages. RESULTS: Mean scores for all
belief scales generally showed a linear, monotonic increase across the six stages.
Percent difference between the first and last stage ranged from a low of 7.5% for
trust in physician scale to a high of 24.2% for perceived value of prescription med-
ications. Multivariate analyses found significant differences in scale scores across
the stages for all seven scales (p0.001). CONCLUSIONS: Our results provide pre-
liminary validation of a novel approach to frame longitudinal persistence to
chronic medications. This study demonstrates that patients’ beliefs may help pre-
dict not onlywhether they discontinue therapy but alsowhen theymay discontinue
the prescribed therapy. Improving medication beliefs may help to move patients
gradually along the continuum from early non-persistence to perfect adherence.
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OBJECTIVES: Health utility may improve over time after initiation of BoNTA treat-
ment as injection dose and location are optimized leading to a steady state. The
BOTOX Exposure Index (BEI) was developed to model the longitudinal effect of
previous BoNTA exposure on health utility.METHODS: The MOBILITY study mea-
sures health utility via the SF-6D in naïve and previously-treated (maintenance)
patients receiving BoNTA for various indications, including spasticity, hyperhidro-
sis, and dystonias. Treatment history, SF-12v2 Physical (PCS) and Mental (MCS)
Component Summary scores, and SF-6Dwere reported. The BEIwasmodeled using
interim study data from 795 patients. The BEI of a patient treated with dose (d)
units/treatment and number (n) of previous treatment cycles is: BEIn●d●f(x;)dx
integral tf to tl where tf and tl are the time (yrs) from the first and last injections
before baseline and  is the shape parameter that characterizes the expected du-
ration of time that the treatment effect remains. The BEI was then standardized to
reduce variation across indications. RESULTS: Logarithmic transformation of the
BEI resulted in a more normalized distribution of BoNTA exposure, and allowed
categorization into low (0.5 standard deviations (SD) from themean exposure),
moderate (0.5 – 0.5 SD), and high ( 0.5 SD) BEI. Among 285 naïve patients, the BEI
was significantly associatedwith the change in SF-6D (p0.004), PCS (p0.007), and
MCS (p0.046). Among maintenance patients with a low (n205), moderate
(n285) or high BEI (n181), improvements in SF-6D were associated with moder-
ate BEI (p0.020) and improvements in MCS with low BEI (p0.021).
CONCLUSIONS: The BEI is associated with improvement in PCS, MCS and SF-6D
scores in naïve patients, and improvement in selected scores in the maintenance
population. Overall, the BEI model suggests health utility improves in naïve pa-
tients, whereas patients on an established treatment regimen are more likely to
sustain their existing SF-6D and component scores.
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